
OM-85 did not prevent preschool wheezing illness in the ORBEX trial
AI-summarized from the linked source. Educational brief, not medical advice.
Brief summary
In a double-blind randomized trial of infants at increased risk for asthma, two years of oral OM-85 did not delay or reduce the first wheezing lower respiratory tract illness during the following three years compared with placebo.
What NurseJet pulled from the source
The ORBEX trial randomized 822 children aged 6 to 18 months. During the off-treatment observation period, wheezing illness occurred in 71 of 342 children in the OM-85 group and 61 of 339 in the placebo group (HR 1.16; 95% CI 0.82 to 1.64), with no significant difference in the primary outcome.
Why this matters for nurses
Families of young children at elevated asthma risk may ask about products promoted to prevent future wheezing. This large trial does not support presenting OM-85 as an effective primary-prevention strategy for asthma-like symptoms in this population.
Bedside takeaway
Do not present OM-85 as proven prevention for preschool wheezing; reinforce the child's prescribed respiratory plan instead.
Key takeaways
- Children received OM-85 or placebo for 10 days each month over 24 months, followed by 36 months of observation off treatment.
- The trial did not find a significant difference in time to first wheezing lower respiratory tract illness during observation.
- Fevers, coughs, and colds were the most frequent adverse events and did not differ between groups.
Practice implications
- Use the child's prescribed wheeze or asthma action plan for symptom recognition and escalation, and avoid suggesting bacterial lysate products as proven primary prevention. Direct product questions to the pediatric clinician and follow local respiratory-care protocols.
Limitations & cautions
- The trial enrolled children with selected asthma-risk factors at 11 U.S. academic sites, and 596 of 822 randomized children completed the full observation period. The result addresses OM-85 for primary prevention in this population, not treatment of established asthma or acute wheezing.
- AI-summarized from the linked source. Review the original article before applying to practice.
Citations
Exact source links
Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.
Lancet (PubMed)
Lancet (PubMed). Use of the bacterial lysate OM-85 for the primary prevention of wheezing lower respiratory illness in preschool children: a randomised, placebo-controlled trial.
https://pubmed.ncbi.nlm.nih.gov/42705251/
Professional education only


